Deuchar, Graeme A.
van Kralingen, Josie C.
Work, Lorraine M.
Santosh, Celestine
Muir, Keith W.
McCabe, Chris
Macrae, I. Mhairi
Funding for this research was provided by:
Chief Scientist Office, NHS Scotland (ETM/146)
Article History
Received: 23 February 2018
Revised: 13 November 2018
Accepted: 14 November 2018
First Online: 30 November 2018
Compliance with Ethical Standards
: This work was supported by an award from the Chief Scientist Office, NHS Scotland (ETM/146). All experiments were approved by the University of Glasgow Ethical Review Panel and performed under a licence from the UK Home Office and subject to the Animals (Scientific Procedures) Act, 1986 incorporating European Directive 2010/63/EU.
: Authors CS and GAD are inventors on patents relating to the use of PFCs and MRI technology with hyperoxia, to determine the metabolic state of different tissue compartments in the ischaemic brain using GOLD imaging technology. CS, CM and GAD declare ownership of stock in Aurum Biosciences Ltd., the company developing and commercialising GOLD imaging technology.